Scholarlink

<p>This preliminary study explores a dual strategy of augmenting anticancer therapy with Carboplatin-loaded solid lipid nanoparticles (SLNs) alongside antigen-specific antibodies through immunization of KB oral carcinoma cells. KB and Sp2/01 myeloma cells were cultured and assessed for viability. Female Balb/c mice were immunized with KB cells, resulting in significant weight gainand spleen enlargement, suggesting immune activation. Enzyme-linked immunosorbent assay (ELISA) confirmed the production of antigen-specific antibodies, as indicated by an increase in absorbance at a 1:1000 serum dilution. Splenocytes from immunized mice were fused with myeloma cells using polyethylene glycol (PEG), with optimal hybridoma generation achieved in the third trial. SLNs were formulated by the microemulsion method, which exhibited favourable physicochemical properties (particle size: 144.57&#xa0;nm, PDI: 0.261, zeta potential: -32 mV). Cytotoxicity assays revealed time- and dose-dependent cytotoxic effects against oral squamous cell carcinoma (OSCC), with SLNs demonstrating greater potency compared to free Carboplatin. These findings underscore the promise of SLNs in cancer therapy and the generation of KB cell-targeting antibodies using hybridoma technology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Production of monoclonal antibodies (mAbs) against oralcarcinoma & its bioconjugation with solid lipid nanoparticles (SLN) for drug delivery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月26日

查看全文
  • Sanskruti Shrenik Patil,
  • Kusuma Kumari Garikapati,
  • Tallapaneni Vyshnavi,
  • Abhishek Dey,
  • Vasanth Raj Palanimuthu

摘要

This preliminary study explores a dual strategy of augmenting anticancer therapy with Carboplatin-loaded solid lipid nanoparticles (SLNs) alongside antigen-specific antibodies through immunization of KB oral carcinoma cells. KB and Sp2/01 myeloma cells were cultured and assessed for viability. Female Balb/c mice were immunized with KB cells, resulting in significant weight gainand spleen enlargement, suggesting immune activation. Enzyme-linked immunosorbent assay (ELISA) confirmed the production of antigen-specific antibodies, as indicated by an increase in absorbance at a 1:1000 serum dilution. Splenocytes from immunized mice were fused with myeloma cells using polyethylene glycol (PEG), with optimal hybridoma generation achieved in the third trial. SLNs were formulated by the microemulsion method, which exhibited favourable physicochemical properties (particle size: 144.57 nm, PDI: 0.261, zeta potential: -32 mV). Cytotoxicity assays revealed time- and dose-dependent cytotoxic effects against oral squamous cell carcinoma (OSCC), with SLNs demonstrating greater potency compared to free Carboplatin. These findings underscore the promise of SLNs in cancer therapy and the generation of KB cell-targeting antibodies using hybridoma technology.